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ABSTRACT: Seroma formation is a well-recognized postoperative
complication for many plastic and general surgical procedures.
Although various tissue adhesives and substances have been used in
an effort to treat seroma formation, no therapies have been
established clinically. Recently, the nano-bridging phenomenon has
been introduced as a promising approach to achieve tissue adhesion
and strong closure of deep skin wounds in rats. The present study
seeks to assess the potential of nano-bridging beyond skin wounds in
a rat model of seroma. Seromas were induced in 20 Lewis rats
through bilateral axillary lymphadenectomy, excision of the
latissimus dorsi and cutaneous maximus muscles, and disruption
of dermal lymphatics. On postoperative day (POD) 7, the seroma
was aspirated on both sides. A bioactive nanoparticle (NP)
suspension based on zinc-doped strontium-substituted bioglass/ceria nanoparticles (NP group) or fibrin glue (fibrin group) was
injected into the right seroma cavity, while the left side was left untreated. On POD 14, the NP group showed complete remission
(no seromas at all), while the fibrin group recorded a reduction of only 63% in the seroma fluid volume. The NPs exerted local anti-
inflammatory and neo-angiogenic effects, without any detectable systemic changes. Moreover, the ceria levels recorded in the organs
did not surpass the background level, indicating that the nanoparticles stayed at the site of application. This study is a promising first
example demonstrating the ability of inorganic nanoparticle formulations to reduce seroma formation in a rat model, without any
detectable systemic adverse effects. These results emphasize the potential of nanotechnological solutions in the therapeutic
management of seroma in the clinical setting.
KEYWORDS: seroma, mixed metal oxide nanoparticles, animal model
■ INTRODUCTION
Seroma formation is a common yet poorly understood
postoperative complication caused by the accumulation of
serous fluid following the dissection of extensive skin flaps.
Seromas most commonly occur following abdominoplasty
(removal of excess skin and fat from the middle and lower
abdomen mostly for cosmetic purposes),1,2 mastectomy
(removal of breast tissue) with or without the removal of the
axillary lymph nodes,3 and at the donor site after harvesting the
latissimus dorsi muscle for reconstructive purposes.4 Seroma
formation is a serious postoperative complication recorded in
up to 79% of the patients.5 Because of its high frequency,
surgeons have started to consider it a side effect rather than a
complication. The therapeutic management is stressful and
time-consuming for patients and physicians alike and includes
prolonged hospital stays due to the required drainage,
associated wound healing problems, repeated admissions to
the hospital, and additional corrective surgeries.6 The exact
pathogenesis of seroma formation is still under debate.
Seromas are generally considered to be formed by the
accumulation of the lymphatic fluid.7−9 However, several
studies have also traced their origin back to surgical trauma
and the resulting acute inflammatory exudation.10,11 Various
studies have explored the use of tissue adhesives and
substances such as methylprednisolone,12 Mytilus edulis
protein,13 and lysine-derived urethane14 in attempts to reduce
postoperative seroma formation. However, the aforementioned
approaches failed to establish a clinical standard.
A commonly investigated pathway in the pathogenesis of
seroma and the treatment thereof is the plasmin system and
the components of the coagulation cascade.15,16 Specifically,
the lack of fibrinogen observed on the first postoperative day
(POD) has been supplemented with fibrin glue to promote
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coagulation.4,17 Supplementation with coagulation factors has
been attempted in several studies, however, with heteroge-
neous results. Kulber et al.17 have previously proven the
adhesive efficacy of fibrin glue in rat models; however, the
fibrin adhesives ultimately failed to show any benefit in
minimizing seromas in a randomized controlled trial in the
clinical setting.4 The combination of quilting sutures and fibrin
glue is one of the most common techniques used to tackle
postoperative seromas.18 Although promising with regard to its
efficiency in reducing postoperative seroma formation, the
costs of fibrin glue19 and the added surgical time necessary for
the quilting sutures20 are major drawbacks of this approach.
Another tenet is based on preventing the degradation of
already formed fibrin complexes around the vessels by
fibrinolytically active components of the plasma. By inhibiting
fibrin degradation, additional accumulation of exudate can be
prevented. For example, tranexamic acid, an antifibrinolytic
agent, has been tested in a randomized controlled trial but
failed to show any statistically significant difference,15 despite
the promising concept.
Nanotechnology and nanoparticle (NP) engineering offer
numerous new opportunities for clinics. The small dimensions
of the nanoparticles, as well as their controllable surface
characteristics, can be harnessed for medical purposes.21
Leibler et al.22 have recently introduced the concept of
nano-bridging based on tissue adhesion on the large external
surface area of inorganic silica and iron oxide nanoparticles,
which then leads to macroscopic tissue gluing. They showed
that the nano-bridging phenomenon can be harnessed to
achieve tissue adhesion and strong closure of deep wounds in
the skin and liver. More recently, the concept of nano-bridging
has been extended from inert nanoparticles to nanomaterials
exhibiting potent bioactivity, including bioglass/cerium oxide-
based hybrid nanoparticles.23 In a recent study,24 we showed
that the inherent procoagulant,23 neo-angiogenic, and anti-
inflammatory properties of zinc-doped strontium-substituted
bioglass/ceria nanoparticles lead to increased skin flap survival
in a rat model. Therefore, the prospect of extending nano-
bridging to bioactive nanoparticles with procoagulant and
tissue regenerative properties for the prevention of seroma is
promising. These zinc-doped strontium-substituted bioglass/
ceria nanoparticles unify the angiogenic and soft tissue
regeneration properties of bioglass25,26 with endothelial cell
proliferation and vascular sprouting induction, as well as
antioxidant properties of ceria.23,27 Although both zinc28,29 and
strontium30,31 have angiogenic properties, zinc additionally
Figure 1. (a, b) Posterior axillary lines were marked on both sides. (c) 3 cm skin incision. (d) Identification of the cutaneous maximus muscle (blue
arrow). (e) Muscle was removed 1 cm on each side of the incision. To disrupt the dermal lymphatics, the undersurface of the skin was scraped with
a scalpel. (f) Identification of latissimus dorsi muscle (black arrow). (g) Excision of latissimus dorsi muscle. (h) Identification and removal of
axillary lymph nodes (purple arrow).
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exhibits anti-inflammatory activity.32,33 Importantly, zinc-
doped strontium-substituted bioglass/ceria nanoparticles can
be produced in a scalable and sterile high-temperature flame
spray pyrolysis process, fulfilling many of the prerequisites for
later clinical translation.34,35
This study aimed to assess the ability of bioactive inorganic
nanoparticle-based formulations to reduce seroma formation in
a rat model, in direct comparison to one of the most frequently
used clinical treatment and the current gold standard, fibrin
glue.
■ MATERIALS AND METHODS
Nanoparticle Synthesis. The zinc-doped strontium-substituted
bioglass/ceria nanoparticles (NPs) were produced by flame spray
pyrolysis according to previously described methods.23,24 In short,
calcium 2-ethylhexanoate, sodium 2-ethylhexanoate, tributyl phos-
phate, hexamethyldisiloxane, strontium acetylacetonate hydrate, Ce-2-
ethylhexanoate, and zinc acetylacetonate were diluted in tetrahy-
drofuran (THF) and sprayed through a nozzle. The created droplets
were ignited by a flame and the nanoparticles were collected
downstream after a nucleation process.
Nanoparticle suspension was prepared by ultrasonication immedi-
ately before application, at 20% amplitude for 4 min, with a 70%
power cycle (device: Sonopuls HD 4020, Bandelin electronic GmbH
& Co. KG, Berlin. Set for volumes from 20 to 900 mL; ultrasonic
nominal output max. 200 W, ultrasonic generator GM 4200,
ultrasonic converter UW 200, booster horn SH 200 G, and titanium
flat tip TT 213, diameter 13 mm).
Nanoparticle Characterization. Nanoparticle characterization
was performed similarly as described in a previous study.36 Scanning
transmission electron micrographs and energy-dispersive X-ray
spectroscopy (EDS) elemental distribution maps of the as-prepared
nanoparticles were recorded on a Talos F200X transmission electron
microscope (TEM, Super-X EDS, four detector configuration, FEI)
with an accelerating voltage of 200 kV. X-ray diffraction measure-
ments were performed with a Bruker D8 advance diffractometer (40
kV, 40 mA, Cu Kα radiation) at 2q = 10−70°. Dynamic light
scattering (DLS) hydrodynamic size and ζ potential measurements
were performed with a Zetasizer (Nano ZS90, Malvern Instruments).
Raman spectra of the nanoparticles were measured on a WITec Alpha
300R confocal Raman microscope with a UHTS 300 Vis spectrometer
and an Andor Newton EMCCD. Fourier transform infrared (FTIR)
spectra were collected using a Varian 640-IR spectrometer.
For elemental analysis, the as-prepared nanoparticles were
weighted into poly(tetrafluoroethylene) tubes and mixed with 6 mL
of 65% HNO3 p.a. (Merck) and 1 mL of 30% H2O2 p.a. (Merck). The
samples were subsequently digested in a microwave and elements
were quantified by inductively coupled plasma optical emission
spectrometry (ICP-OES, Agilent 5110, Santa Clara, CA). Owing to
the high silicate content and thus incomplete Si dissolution, the Si
percentage was underestimated in some samples. For these samples,
the residual mass was assumed to be Si as well. Other elements did
not show incomplete recovery rates.
Surgical Model. First, a seroma model was developed by
combining the techniques reported in the literature.13,17,37−39 Starting
from the model described by Kulber et al.,17 a bilateral model was
envisioned: an incision was placed in the posterior axillary line, the
cutaneous maximus and latissimus dorsi muscles were excised, and
additional axillary lymphadenectomy was undertaken. The undersur-
face of the skin flap was scraped with a scalpel as described by Chung
et al.13 After hemostasis was achieved, the skin was closed with
interrupted mattress sutures (Figure 1). This model allowed us to
have an intraindividual comparison, with one side being used as
control, while on the contralateral side of the same animal the
treatment (either the nanoparticles or fibrin glue) was applied 1 week
postoperatively, after the seroma fluid was aspirated.
All surgeries were performed under continuous inhalation
anesthesia. Buprenorphine (50 μg/kg) was administered subcuta-
neously as preemptive analgesia 30 min prior to anesthesia. Isoflurane
at 5% with oxygen (1 L/min) was used for the induction of anesthesia
(2−3 min) in an induction chamber. Then, the animals were placed
on maintenance anesthesia at 1−1.5% isoflurane with 0.6 L/min
oxygen. All of the rats were maintained at normal body temperature
using thermal pads and treated with ophthalmic ointment to both
eyes to prevent desiccation. They were all monitored (respiratory rate,
temperature) until awake. After the operations, rats were kept in a
warm environment using a heating pad for at least 1 h. Buprenorphine
(50 μg/kg) was administered as postoperative analgesia just before
final skin closure and every 12 h until postoperative day (POD) 2.
Further doses of buprenorphine were given if animals showed pain.
Pain or distress was monitored carefully and graded based on a
specially designed score sheet every day until the end of the
experiment (Table S1). This study was conducted according to the
ARRIVE guidelines40 and was approved by the Cantonal Animal
Ethics Committee for Animal Experimentation, Bern, Switzerland
(approval number BE 39/17).
Treatment Groups. Twenty Lewis rats weighing between 200
and 250 g were randomly assigned to two groups: 10 rats received the
NPs as treatment, while the other 10 rats underwent treatment with
fibrin glue (Tisseel, Baxter AG, 8152 Opfikon, Switzerland). The
exact timeline of the study is depicted in Figure 2. Briefly, the rats
were left for 7 days to develop seromas. The left side was used as a
control and the seroma fluid was aspirated, while the right side
underwent injection of either NP or fibrin glue after the aspiration of
the seroma fluid. The NP suspension contained 15 mg of
nanoparticles/1 mL of saline, while the same volume (1 mL) of
fibrin glue was used for the other group. After another 7 days, the two
sides of each rat were inspected and the seroma fluids were aspirated
and collected where they were present. Moreover, ultrasound images
were taken before aspiration to confirm the presence of seroma.
Euthanasia was performed on POD 14, when harvesting of blood,
Figure 2. Experiment timeline. The operation was performed on postoperative day (POD) 0. On the same day, blood samples were collected. After
7 days, the rats developed seromas on both of the operated sides. The left side was used as control and the seroma fluid was aspirated, while the
right side was used as treatment: the seroma fluid was aspirated and either nanoparticles or fibrin glue was injected and massaged in the cavity.
Blood was also collected on this day. Euthanasia was performed on POD 14, when the seromas were aspirated, and various samples were collected
for analysis.
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seroma fluid (if present), seroma capsule, skin, and various organs for
analysis was undertaken.
Cytokine Measurements. Protein extraction was performed as
previously described by our group.24 Briefly, the M tubes (Miltenyi
Biotec GmbH, Bergisch Gladbach, Germany) containing radio-
immunoprecipitation assay buffer (50 mM Tris−HCl, pH 8.0, with
150 mM sodium chloride, 1.0% Igepal CA-630 (NP40), 0.5% sodium
deoxy cholate, and 0.1% sodium dodecyl sulfate) and protease
inhibitor cocktail (Sigma) were used for skin samples, after being cut
into small samples. The homogenates obtained with a gentle MACS
Dissociator (Miltenyi Biotec GmbH) were incubated on ice and
underwent sonication. The supernatants underwent protein quanti-
fication, using a classical bicinchoninic acid assay. A bovine serum
albumin standard (2.0 mg/mL in 0.9% aqueous NaCl containing
sodium azide, Thermo Fisher Scientific) was prepared and transferred
to a flat transparent 96-well plate (Thermo Fisher Scientific).
Luminex multiple assay (ProcartaPlex Mix&Match Rat 6-Plex) was
performed on tissue samples and plasma was collected on POD 0, 7,
and 14 for the following proteins: vascular endothelial growth factor A
(VEGF-A), interferon-γ (IFN-γ), interleukin-1β (IL-1β), interleukin-4
(IL-4), interleukin-6 (IL-6), interleukin-10 (IL-10), monocyte
chemoattractant protein-1 (MCP-1), and tumor necrosis factor-α
(TNF-α). The procedure was performed based on the original
manufacturer’s instruction manual, and plates were read on a
FLEXMAP 3D system (Luminex, Austin, CA).
Systemic Effects. The aforementioned cytokines, together with
creatinine, alanine aminotransferase (ALAT), and aspartate amino-
transferase (ASAT), were analyzed from plasma collected on POD 0,
7, and 14.
Histological Analysis. Seroma capsules harvested on POD 14
underwent histological analysis after being stained with hematoxylin
and eosin. Inflammation, fibrosis, granulation tissue, the presence of
multinucleated giant cells, edema, congestion, and necrosis were
determined and scored from 0 to 3, with 3 being the most severe.
Elemental Analysis of Organ Samples. Ceria content in the
different rat organs was measured by transferring organ samples to a
polytetrafluoroethylene container and mixing with 6 mL of 65%
HNO3 p.a. (Merck) and 1 mL of 30% H2O2 p.a. (Merck). The
samples were then digested in a microwave and measured on an ICP-
OES instrument (Agilent 5110, Santa Clara, CA).
Statistical Analysis. GraphPad Prism 7 software (GraphPad
Software Inc., La Jolla, CA) was used for statistical analysis. All values
are expressed as mean ± standard error or median with interquartile
range, depending on the distribution of the data. The Shapiro−Wilk’s
test was used to assess data distribution. For the normally distributed
data, comparisons within the same group between the control and the
treatment sides, as well as between the same sides at POD 7 and POD
14, were performed using the paired samples t test. Comparisons
between different groups were performed with the independent
samples t test and ordinary one-way analysis of variance (ANOVA).
For the non-normally distributed data, Wilcoxon signed-rank test was
employed for comparisons among the same group, while the Mann−
Whitney U test and the Kruskal−Wallis test were used for the
between-groups analysis. p values <0.05 were considered to indicate
statistical significance.
■ RESULTS AND DISCUSSION
Inorganic Nanoparticle-Based Formulations Are Pro-
duced in a Controlled Manner. A bioactive nanoparticle
formulation for topical application was prepared from flame-
made mixed metal oxide NPs exhibiting properties optimized
for wound healing purposes. The NPs were prepared by liquid-
feed flame spray pyrolysis (LF-FSP) in one step from
inexpensive liquid precursors.41
Figure 3. (a) High-angle annular dark-field (HAADF) electron micrographs of the nanoparticles including energy-dispersive X-ray spectroscopy
mapping. (b) Dynamic light scattering results of the nanoparticles upon suspension in 10% phosphate-buffered saline (PBS) showing
hydrodynamic diameter and ζ potential. (c) X-ray diffraction pattern showing characteristic ceria peaks. Fourier transform infrared (FTIR)
spectrum with a pronounced broad peak at 1020 cm−1. Raman spectroscopy with a pronounced peak at 465 cm−1, which is a characteristic of ceria.
(d) Elemental composition of the nanoparticles measured by inductively coupled plasma optical emission spectrometry (m: measured, t:
theoretical).
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The physicochemical properties of the as-prepared zinc-
doped strontium-substituted bioglass/ceria nanoparticles are
illustrated in Figure 3. Electron micrographs indicate a
nanoparticle core size in the order of 5−10 nm (Figure 3a).
Energy-dispersive X-ray spectroscopy mapping confirms the
presence of Ce, the Zn dopant, the elements contained in
bioglass (Si, Na, Ca, P), and the Sr substitution (Figure 3a).
Dynamic light scattering of the fractal-like particles in
suspension gives an average hydrodynamic size of 695 ± 75
nm with a ζ potential of −25 ± 1 mV, which is comparable to
similarly produced particles42 (Figure 3b). The powder X-ray
diffraction pattern features the characteristic ceria peaks with
the amorphous part of the bioglass masked by the high
crystallinity of ceria (Figure 3c). On the FTIR spectrum, a
broad peak around 1020 cm−1 is visible, which can be
attributed to Si−O−Si bonds of the SiO4 tetrahedra in a
bioglass framework. The sharp peak around 870 cm−1 is most
likely a carbonate band that is characteristic of CO3
2− groups
in carbonated apatites. The broad peak at 1450 cm−1 can be
assigned to the v3(CO3
2−) band of carbonates adsorbed on the
surface.43 The Raman spectrum shows the pronounced ceria
peak at 460 cm−1. Inductively coupled plasma optical emission
spectrometry of the nanoparticles demonstrates that their
elemental composition is in excellent agreement with the
theoretical values derived from the composition of their liquid
precursor solutions (Figure 3d). Although flame-spray-
synthesized nanoparticles yield process-intrinsic fractal agglom-
erates, which can only partially be broken up, the fractal-like
characteristics (fractal dimension Df of typically 1.9−
2.334,44,45) offer plenty of accessible surface area for proteins
to adhere and interact giving rise to potent procoagulant
properties and to some extent also tissue adhesive properties in
the case of silica-containing (and especially bioglass) nano-
particles.23 The process robustness, scalability, and sterility
offer an attractive route to large-scale production of metal
oxide hybrid nanoparticles, especially for topical applications
where hydrodynamic sizes are less critical.
Seroma Model Leads to Consistent Results. Several
seroma models have been described in the literature. A seroma
formation model in the rat after mastectomy was described in
1992 by Harada et al.;37 however, we consider the incision
placed on the anterior half of the thorax too bothersome for
the rats. Kulber et al.17 recorded a 90% rate of seroma
formation after excising the latissimus dorsi muscle through an
incision placed in the midaxillary line, while another group
recorded a 74% seroma rate when excising the latissimus dorsi
muscle and performing axillary lymphadenectomy through a
posterior midline incision of the thorax.38 Alternatively,
scraping the inner surface of the skin flap for lymphovascular
disruption has also been described.13,39 Only the combination
of the aforementioned techniques (i.e., the latissimus dorsi
excision with lymphadenectomy and scraping of the inner
surface of the flap) allowed us to obtain a 100% reliable rate of
bilateral postoperative seroma, which then served as a model to
investigate the treatment benefits of nanoparticle treatment
(Figure 4). The serous fluid volumes ranged from 0.5 to 2 mL,
with minimal intraindividual left to right differences (mean 0.8
mL, standard deviation (SD) 0.2 mL). Moreover, the pain
scores recorded throughout the experiments ranged from 0 to
2, with scores of 1 and 2 present only on POD 1 and 2, when
the rats received the usual postoperative analgesia. Afterward,
analgesia was not deemed necessary, since all animals had a
daily score of 0 until the end of the experiment.
Zinc-Doped Strontium-Substituted Bioglass/Ceria
Nanoparticles Significantly Reduce Seroma Formation
Compared to Fibrin Glues. Following the establishment of
the seroma model, the experimental nanoparticle-based glue or
fibrin adhesives were applied to treat seromas. Specifically,
fibrin glue or the concentrated NP suspension was injected
directly into the cavity (after aspiration of the seroma fluid),
and the clinical progression during the experiment was
followed. Seroma volume was measured on postoperative day
(POD) 7 and POD 14 by aspiration. The nanoparticle-treated
group did not show any volume on POD 14, translating to a
100% reduction of seroma. In contrast, the fibrin glue group
still recorded seromas in 5 out of the 10 rats, with a seroma
volume reduction of only 63% (Figure 5a), which is in line
with Kulber et al.17 who applied fibrin glue for seroma
treatment in a similar fashion. When analyzing the untreated
control side with the treatment side in the individual rats, we
only reached a statistically significant reduction of seroma fluid
in the NP group, which indicates a larger effect size (Figure
5b). Despite some promising results in seroma reduction in
experimental studies,17 fibrin glue has proven to be inferior, or
even counterproductive46 in clinical studies. Moreover, the
Figure 4. (a) Schematic representation of the seroma cavities on both sides of a rat, with a magnification of the sagittal plane through the lateral
side, depicting skin, seroma cavity, muscle, and the thoracic cavity with the ribs and the intercostal muscles. (b) Representative ultrasound image
depicting a seroma being delineated on the superior side by the skin (red arrow) and the inferior side by the muscle and thoracic cavity (yellow
arrow). The seroma cavity has a length of 1.74 cm and a width of 0.5 cm.
ACS Biomaterials Science & Engineering pubs.acs.org/journal/abseba Article
https://doi.org/10.1021/acsbiomaterials.1c00283
ACS Biomater. Sci. Eng. XXXX, XXX, XXX−XXX
E
costs associated with its use are extremely high for a minor or
nonexistent reduction in seroma formation.19
Although the main principle of reducing seroma focuses on
the anti-inflammatory effects of the substances used, it is
important not to compromise the wound healing process. In
our study, we did not record any wound healing problems, in
contrast to reported treatments with triamcinolone acetonide
or other glucocorticoid-like substances.39 Such drugs might be
suitable for the reduction of seromas; however, the possible
complications associated with their use (e.g., wound infection,
wound dehiscence) may preclude a more regular use in clinical
practice. Note that the zinc-doped strontium-substituted
bioglass/ceria nanoparticles also exhibit potent tissue regener-
ative properties, as recently demonstrated in a skin flap
model.47
Importantly, the rats did not record a pain score higher than
2 throughout the experiments, as assessed through the score
sheet (Table S1). Additional analgesia was therefore not
necessary, in contrast to studies using experimental treatments,
such as OK-432.48 As opposed to the anti-inflammatory action
of the nanoparticles, OK-432 is a sclerotherapeutic agent that
induces inflammation and subsequent sclerosis of the dead
space, causing pain, swelling, and redness at the injection site.48
Anti-Inflammatory and Neo-Angiogenic Effects of
Nanoparticles on Biochemical Analysis Correlate with a
Reduction of Seroma Formation. The seroma capsule
harvested from the nanoparticle group at the end of the
experiment (POD 14) showed a statistically significant
increase in VEGF-A, as well as a decrease in IFN-γ (Figure
6). Since one of the theories behind seroma formation focuses
on an exaggerated inflammatory response,10,11 the anti-
inflammatory effect of the NPs indicated by a mild down-
regulation of the pro-inflammatory cytokine IFN-γ might hint
at a possible mechanism. Similar anti-inflammatory and neo-
angiogenic effects of the zinc-doped strontium-substituted
bioglass/ceria nanoparticles have been found in a perforator
flap model,24 which further supports the proposed mechanism
of action of the nanoparticles. VEGF-A is a potent angiogenic
cytokine, stimulating endothelial cell proliferation. On the one
hand, in the wound healing process, its expression is important
and is mostly warranted by macrophages, representing an
important cytokine, especially in the early stages. On the other
hand, it also enhances vascular permeability, which might lead
to the secretion of various plasma proteins and stimulation of
the granulation tissue.49,50 This increase in permeability by
VEGF might stimulate the accumulation of fluid6 and could
therefore be counterproductive in the treatment of seromas.
However, in our study, the slight upregulation of VEGF-A
correlated with a reduction in seroma formation in the
nanoparticle group.
Since there were no seromas in the nanoparticle group on
POD 14, we were only able to analyze the seroma fluid of the
fibrin group (Figure 7). All of the cytokines, apart from IL-6,
showed increased levels on POD 14 in the treatment group
compared to the contralateral control side. Additionally, IFN-γ,
IL-1β, IL-10, and MCP-1 were significantly increased. The
main role of fibrin glue, a hemostatic agent, in minimizing
seroma formation is based on its ability to seal the open
lymphatic and blood vessels and to close the dead space, but
there is only limited information available in the literature
regarding its effects on inflammation. Although IFN-γ, IL-1β,
and MCP-1 are known for their pro-inflammatory activity, IL-
10 is an anti-inflammatory cytokine and its increase is an
interesting finding. IL-6 is a cytokine that works both as pro-
inflammatory and anti-inflammatory. Its anti-inflammatory
properties are exerted through the downregulation of TNF-α
and the upregulation of IL-10. Although our study did record
an increase in IL-10, we did not see any reduction of TNF-α in
the fibrin group, therefore rendering the interpretation of IL-6
intricate, since overall, the fibrin glue seems to exert a pro-
inflammatory effect.
No Significant Differences in the Histological Anal-
ysis of Seroma Capsule. A mild inflammatory response was
seen in all of the samples, corresponding to postoperative
changes. The lack of multinucleated giant cells confirmed the
absence of foreign body reactions in both the nanoparticle and
fibrin glue groups. Even though we could not identify any
statistically significant difference between the groups when
looking at the seroma capsule from the control side, the fibrin
glue-treated side, and the nanoparticle-treated side, there was a
trend of decreased inflammation in the nanoparticle group,
with a mean score of 1.7 ± 0.6, while the fibrin group recorded
a 2.1 ± 0.8 mean value.
Biodistribution by Elemental Analysis Shows no
Clearance to Other Organs. To assess whether nano-
particles would be redistributed to other organs following
topical application, elemental analysis on tissues was performed
by inductively coupled plasma spectroscopy. Elemental ceria
Figure 5. (a) Seroma formation reduction in the fibrin and
nanoparticle groups between postoperative (POD) 7 and 14. On
POD 7, seroma was aspirated on the treatment-designated side and
either fibrin or nanoparticles were injected in the cavities. At POD 14,
the amount of fluid was again quantified through aspiration. Data
presented as median and range, *p < 0.05, **p < 0.01, by Wilcoxon
matched-pairs signed rank test. (b) Seroma formation in the fibrin
and nanoparticle groups on POD 14a comparison between the
control side and the treatment-designated side. Data presented as
median and range, *p < 0.05, by Mann−Whitney test.
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(Ce) was found to be a reliable tracer of such nanoparticles in
tissue.36 Ce values are standardized to express elemental Ce
contents relative to organ weight in parts per million (ppm)
(Figure 8). The main finding is that there is no redistribution
of the nanoparticles to the organs, indicating that the
nanoparticles likely remain at the initial site of application
Figure 6. Biochemical analysis of the seroma capsule. The seroma capsule was harvested on postoperative day 14 from the control side (Control)
and from the treatment sides in both groups (Fibrin: fibrin glue group; NP: nanoparticle group). Data presented as mean and SD, *p < 0.05, by
one-way ANOVA with Tukey’s post hoc multi-comparisons test. (L-4, IL-6, and IL-10 were below the detection level).
Figure 7. Biochemical analysis of seroma fluid in the fibrin group. The aspirated seroma fluid was collected on postoperative day (POD) 7 and
POD 14. Although on POD 7 there was seroma fluid on both sides of the rats and in both groups, on POD 14 we only recorded seroma fluid on
the control side of both groups (POD 14 Control) and on the treatment side of the fibrin glue group (POD 14 Fibrin). In the nanoparticle group,
the seroma resolved on the treatment side on POD 14 and therefore we did not record any seroma fluid here. Data presented as mean and SD, *p <
0.05, by one-way ANOVA with Tukey’s post hoc multi-comparisons test.
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(skin and capsule of the seroma on the right side). Moreover,
the Ce levels recorded in the organs remained at the
background level found in fibrin-treated rats (<0.01 ppm
(μg/L), which is the lower limit of detection). It is noteworthy,
however, that in the case of 1 out of 10 rats, Ce levels above
the noise were found in the liver, kidney, and spleen. This can
likely be attributed to the entering of nanoparticles into a
blood vessel during application. The risk and potentially
Figure 8. Ceria content in the organs and seroma capsule in the fibrin group and the nanoparticle group (NP group). Data presented as mean and
SD.
Figure 9. Microcomputed tomography (microCT). Skin capsule of the right treated side of a rat in the nanoparticle group: accumulations of
particles visible.
Figure 10. Plasma cytokine levels. Plasma analysis was undertaken at various time points: postoperative day (POD) 0 or operation day, POD 7, and
POD 14, in both the fibrin glue group and the nanoparticle (NP) group. Data presented as mean and SD, *p < 0.05, by one-way ANOVA with
Tukey’s post hoc multi-comparisons test.
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associated side effects of such an unwanted event, although
presumably rare, requires careful consideration and long-term
studies. X-ray microtomography scans confirm the accumu-
lation of nanoparticles within the right (treated) skin capsule
(Figure 9). No indications of nanoparticle depositions were
found in untreated skin capsules or lymph nodes.
Nanoparticle Treatment Has No Systemic Effect
While Fibrin Glue Treatment Increases Systemic
Expression of Inflammatory Cytokines. Importantly,
systemic organ damage markers, such creatinine, ALAT, and
ASAT plasma levels, remained unaltered during the experi-
ments in all groups (Figure S1), with no differences recorded
at POD 7 and 14 when compared to the values obtained at the
beginning of the experiment (POD 0).
The plasma cytokine levels did not record any differences
when comparing the results of the nanoparticle group at POD
14, 7, and 0 (baseline) (Figure 10), thus emphasizing the lack
of systemic effects of the nanoparticle administration.
However, for the fibrin group, we recorded a statistically
significant increased inflammatory response: IL-1β, MCP-1,
and TNF-α had higher levels at POD 14 when compared to
POD 7 and/or POD 0. These results highlight the fact that
fibrin effects are not limited to the administration site, in
contrast to the nanoparticle formulation, which seems to
exclusively exert its anti-inflammatory and neo-angiogenic
properties locally. Moreover, these findings are in line with the
cytokine levels in the seroma fluid, which also showed mainly
an upregulation of the pro-inflammatory cytokines in the fibrin
group.
Limitations. Although the nanoparticles proved effective at
reducing seroma formation, our study only evaluates the early
postoperative period. Long-term studies would be necessary to
determine whether this effect will last, or whether seromas
could develop at a later stage. Moreover, even though we
demonstrated the anti-inflammatory and neo-angiogenic effects
of the nanoparticles through cytokine environment alterations,
a more thorough understanding of the exact mechanism of the
nanoparticles, and especially the risks associated with their use,
is needed. In terms of formulation, the nanoparticles were
dispersed in saline immediately before application. The
development of a clinically friendlier application method
would be worthwhile investigating to avoid the need for an
ultrasonicator in the clinical setting that might not be so
appealing to the clinicians. It is also noteworthy that while the
nanoparticles can be produced from inexpensive precursors,
the development will eventually drive the costs of a clinical
nanoparticle product. Only a clinical study in direct
comparison of the gold standard treatment based on fibrin
glue will yield the clinical value and cost-effectiveness.
■ CONCLUSIONS
In summary, this work is a promising first example
demonstrating the ability of inorganic nanoparticle-based
formulations to reduce seroma formation in a newly developed,
effective rat model. The application of the nanoparticle
suspension 1 week after the surgery and after aspiration of
the already formed seroma fluid translates into local attenuated
inflammation and complete treatment of seroma, with no
detectable systemic effects. Therefore, provided that these
nanoparticle-based formulations are proven safe, the surgical
field would benefit from the incorporation of these bioactive
inorganic nanoparticles into the therapeutic management of
seroma, a frequent postoperative complication.
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